Physician profile
Deepak R Talreja
NPI 1760451611
$1,493,147.54
in general payments reported to CMS, 2019-2025
47 companies · $234K in 2025
The $234K reported for 2025 was more than what 99% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $206K · 2020: $184K · 2021: $231K · 2022: $231K · 2023: $218K · 2024: $189K · 2025: $234K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $496K · Consulting Fee: $60K · Travel and Lodging: $55K · Food and Beverage: $21K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,813 · Long Term Medical Supply Or Device Loan: $711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $495,917.39 |
| Consulting Fee | $60,117.62 |
| Travel and Lodging | $54,982.26 |
| Food and Beverage | $21,034.81 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,812.50 |
| Long Term Medical Supply Or Device Loan | $710.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $288,929.60 | 2021-2025 | Corevalve Evolut R, Harmony, Symplicity G3 |
| Lilly USA, LLC | $242,129.59 | 2019-2025 | Jardiance, Zepbound |
| Novo Nordisk INC | $106,809.23 | 2023-2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97,049.83 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $81,800.58 | 2019-2024 | Farxiga, Fasenra |
| Bayer Healthcare Pharmaceuticals INC. | $76,026.57 | 2021-2025 | |
| Amgen INC. | $69,879.16 | 2019-2025 | Repatha, Repatha |
| Regeneron Healthcare Solutions, INC. | $68,338.05 | 2019-2025 | Evkeeza |
| E.R. Squibb & Sons, L.L.C. | $66,864.44 | 2019-2025 | Camzyos |
| Janssen Pharmaceuticals, INC | $66,501.14 | 2019-2023 | Xarelto |
| Abbott Laboratories | $62,958.16 | 2019-2025 | Navitor, Portico, Jeti All In One Non-Sterile Kit |
| Medtronic Vascular, INC. | $51,962.79 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $47,068.97 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31,469.59 | 2019-2025 | Lifevest |
| Kiniksa Pharmaceuticals, Ltd. | $30,124.18 | 2021-2023 | Arcalyst |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $27,027.99 | 2020-2023 | Nexletol |
| Novartis Pharmaceuticals Corporation | $17,445.29 | 2019-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $10,795.43 | 2024 | Arcalyst |
| Regeneron Pharmaceuticals, INC. | $9,230.00 | 2024 | Evkeeza |
| Pfizer INC. | $8,988.38 | 2019-2020 | |
| Medicure Pharma INC. | $6,800.00 | 2020-2022 | |
| Scpharmaceuticals INC. | $5,813.84 | 2024 | |
| Boston Scientific Corporation | $4,456.24 | 2019-2025 | Avvigo Guidance System, Opticross, Watchman Flx |
| Edwards Lifesciences Corporation | $4,223.25 | 2019-2025 | Evoque, Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Abiomed | $1,933.90 | 2019-2025 | Impella |
| Merck Sharp & Dohme LLC | $1,907.50 | 2021 | |
| Eko Health, INC. | $1,227.00 | 2022-2023 | |
| Biotronik INC. | $1,124.37 | 2019-2023 | Orsiro Mission, Amvia Edge |
| Siemens Medical Solutions USA, INC. | $862.22 | 2020-2022 | |
| Celgene Corporation | $600.00 | 2022 | |
| Cardiovascular Systems INC. | $576.98 | 2019-2023 | Diamondback Coronary |
| Philips North America LLC | $497.86 | 2019-2025 | (Bq9) Coronary Ivus, Coronary Other |
| Shockwave Medical, INC | $374.42 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Irhythm Technologies, INC. | $324.40 | 2019-2023 | Zio Xt Patch |
| Corindus INC. | $263.10 | 2019 | |
| Impulse Dynamics (USA) INC. | $206.85 | 2022 | |
| Amarin Pharma, INC. | $174.47 | 2019-2023 | |
| Zoll Circulation INC | $113.30 | 2025 | Therox Ds2 Console, Catheter, Downstream Cartridge |
| Braemar Manufacturing, LLC | $71.76 | 2019 | |
| Janssen Scientific Affairs, LLC | $65.73 | 2019-2022 | |
| Osprey Medical INC | $33.53 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $29.58 | 2019 | |
| Cordis US Corp. | $26.89 | 2025 | Mynx Control Venous |
| Aegerion Pharmaceuticals, INC. | $23.72 | 2019 | |
| Nuwellis, INC. | $16.83 | 2019 | |
| Travere Therapeutics, INC. | $0.83 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$211.89 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Talreja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.